Antipsychotic drug effects in schizophrenia: A review of longitudinal FMRI investigations and neural interpretations

Current Medicinal Chemistry

Volumn 20, Issue 3, 2013, Pages 428-437

  Abbott, C C ^a   Jaramillo, A ^a   Wilcox, C E ^a   Hamilton, D A ^b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Antipsychotics; BOLD signal; Drug effects; Functional magnetic resonance imaging; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; EPOXYICOSATRIENOIC ACID; FLUPHENAZINE; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID; NEUROLEPTIC AGENT; OLANZAPINE; POTASSIUM; PROSTAGLANDIN; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

AMYGDALOID NUCLEUS; ANTERIOR CINGULATE; ARTICLE; ASTROCYTE; BINDING AFFINITY; BOLD SIGNAL; BRAIN BLOOD FLOW; BRAIN FUNCTION; CHRONIC DRUG ADMINISTRATION; CORPUS STRIATUM; DEFAULT MODE NETWORK; DOPAMINERGIC NERVE CELL; DRUG ANTAGONISM; DRUG DOSE TITRATION; DRUG EFFECT; DRUG RECEPTOR BINDING; FRONTAL EYE FIELD; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; MOTOR CORTEX; NEUROTOXICITY; NUCLEUS ACCUMBENS; POSITIVE AND NEGATIVE SYNDROME SCALE; PREFRONTAL CORTEX; PSYCHOPHARMACOTHERAPY; RECEPTOR BLOCKING; RECEPTOR DENSITY; RECEPTOR UPREGULATION; SCHIZOPHRENIA; SENSORIMOTOR CORTEX; SUPPLEMENTARY EYE FIELD; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; THALAMUS; VASODILATATION; WORKING MEMORY;

EID: 84877988623     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867311320030014     Document Type: Article

References (109)

1. Tamminga, C.A.; Thomas, B.P.; Chin, R.; Mihalakos, P.; Youens, K.; Wagner, A.D.; Preston, A.R., Hippocampal novelty activations in schizophrenia: Disease and medication effects. Schizophrenia research, 2012, 138, (2-3), 157-163.
2. Hofer, A.; Weiss, E.M.; Golaszewski, S.M.; Siedentopf, C.M.; Brinkhoff, C.; Kremser, C.; Felber, S.; Fleischhacker, W.W., Neural correlates of episodic encoding and recognition of words in unmedicated patients during an acute episode of schizophrenia: a functional MRI study. The American journal of psychiatry, 2003, 160, (10), 1802-1808. (Pubitemid 41103314)
3. van Veelen, N.M.; Vink, M.; Ramsey, N.F.; Kahn, R.S., Left dorsolateral prefrontal cortex dysfunction in medication-naive schizophrenia. Schizophrenia research, 2010, 123, (1), 22-29.
4. Abbott, C.; Juarez, M.; White, T.; Gollub, R.L.; Pearlson, G.D.; Bustillo, J.; Lauriello, J.; Ho, B.; Bockholt, H.J.; Clark, V.P.; Magnotta, V.; Calhoun, V.D., Antipsychotic dose and diminished neural modulation: A multi-site fMRI study. Progress in neuro-psychopharmacology & biological psychiatry, 2010.
5. Strange, P.G., Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacological reviews, 2001, 53, (1), 119-133. (Pubitemid 32173111)
6. Gardner, D.M.; Baldessarini, R.J.; Waraich, P., Modern antipsychotic drugs: a critical overview. CMAJ, 2005, 172, (13), 1703-1711. (Pubitemid 40896865)
7. Seeman, P., Atypical antipsychotics: mechanism of action. Can J Psychiatry, 2002, 47, (1), 27-38. (Pubitemid 34302921)
8. Richelson, E., Receptor pharmacology of neuroleptics: relation to clinical effects. The Journal of clinical psychiatry, 1999, 60 Suppl 10, 5-14. (Pubitemid 29237170)
9. Roth, B.L.; Sheffler, D.J.; Kroeze, W.K., Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature reviews. Drug discovery, 2004, 3, (4), 353-359. (Pubitemid 38499762)
10. Roder, C.H.; Hoogendam, J.M.; van der Veen, F.M., FMRI, antipsychotics and schizophrenia. Influence of different antipsychotics on BOLD-signal. Curr Pharm Des, 2010, 16, (18), 2012-2025.
11. Logothetis, N.; Pauls, J.; Augath, M.; Trinath, T.; Oeltermann, A. In Nature, 2001; Vol. 412, pp 150-157.
12. Logothetis, N.K., What we can do and what we cannot do with fMRI. Nature, 2008, 453, (7197), 869-878. (Pubitemid 351832564)
13. Attwell, D.; Buchan, A.M.; Charpak, S.; Lauritzen, M.; Macvicar, B.A.; Newman, E.A., Glial and neuronal control of brain blood flow. Nature, 2010, 468, (7321), 232-243.
14. Filosa, J.A.; Bonev, A.D.; Straub, S.V.; Meredith, A.L.; Wilkerson, M.K.; Aldrich, R.W.; Nelson, M.T., Local potassium signaling couples neuronal activity to vasodilation in the brain. Nature neuroscience, 2006, 9, (11), 1397-1403. (Pubitemid 44646212)
15. Gordon, G.R.; Choi, H.B.; Rungta, R.L.; Ellis-Davies, G.C.; MacVicar, B.A., Brain metabolism dictates the polarity of astrocyte control over arterioles. Nature, 2008, 456, (7223), 745-749.
16. Wise, R.G.; Tracey, I., The role of fMRI in drug discovery. J Magn Reson Imaging, 2006, 23, (6), 862-876. (Pubitemid 43825441)
17. Khan, Z.U.; Koulen, P.; Rubinstein, M.; Grandy, D.K.; Goldman-Rakic, P.S., An astroglia-linked dopamine D2-receptor action in prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, (4), 1964-1969. (Pubitemid 32165606)
18. Missale, C.; Nash, S.R.; Robinson, S.W.; Jaber, M.; Caron, M.G., Dopamine receptors: from structure to function. Physiological reviews, 1998, 78, (1), 189-225. (Pubitemid 28070979)
19. Beaulieu, J.M.; Gainetdinov, R.R., The physiology, signaling, and pharmacology of dopamine receptors. Pharmacological reviews, 2011, 63, (1), 182-217.
20. Spano, P.F.; Govoni, S.; Trabucchi, M., Studies on the pharmacological properties of dopamine receptors in various areas of the central nervous system. Advances in biochemical psychopharmacology, 1978, 19, 155-165.
21. Kebabian, J.W.; Calne, D.B., Multiple receptors for dopamine. Nature, 1979, 277, (5692), 93-96. (Pubitemid 9093798)
22. Wolf, M.E.; Roth, R.H., Autoreceptor regulation of dopamine synthesis. Annals of the New York Academy of Sciences, 1990, 604, 323-343.
23. Amenta, F.; Ricci, A.; Vega, J.A., Autoradiographic localization of dopamine receptors in rat cerebral blood vessels. Eur J Pharmacol, 1991, 192, (1), 123-132.
24. Krimer, L.S.; Muly, E.C., 3rd; Williams, G.V.; Goldman-Rakic, P.S., Dopaminergic regulation of cerebral cortical microcirculation. Nature neuroscience, 1998, 1, (4), 286-289.
25. Brassen, S.; Tost, H.; Hoehn, F.; Weber-Fahr, W.; Klein, S.; Braus, D.F., Haloperidol challenge in healthy male humans: a functional magnetic resonance imaging study. Neurosci Lett, 2003, 340, (3), 193-196. (Pubitemid 36369671)
26. Pessiglione, M.; Seymour, B.; Flandin, G.; Dolan, R.J.; Frith, C.D., Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature, 2006, 442, (7106), 1042-1045. (Pubitemid 44330261)
27. Menon, M.; Jensen, J.; Vitcu, I.; Graff-Guerrero, A.; Crawley, A.; Smith, M.A.; Kapur, S., Temporal difference modeling of the blood-oxygen level dependent response during aversive conditioning in humans: effects of dopaminergic modulation. Biological psychiatry, 2007, 62, (7), 765-772. (Pubitemid 47381433)
28. Abler, B.; Erk, S.; Walter, H., Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, doubleblind, placebo-controlled fMRI study. Psychopharmacology, 2007, 191, (3), 823-833. (Pubitemid 46355905)
29. Tost, H.; Meyer-Lindenberg, A.; Klein, S.; Schmitt, A.; Hohn, F.; Tenckhoff, A.; Ruf, M.; Ende, G.; Rietschel, M.; Henn, F.A.; Braus, D.F., D2 antidopaminergic modulation of frontal lobe function in healthy human subjects. Biological psychiatry, 2006, 60, (11), 1196-1205. (Pubitemid 44693536)
30. Tost, H.; Braus, D.F.; Hakimi, S.; Ruf, M.; Vollmert, C.; Hohn, F.; Meyer-Lindenberg, A., Acute D2 receptor blockade induces rapid, reversible remodeling in human cortical-striatal circuits. Nature neuroscience, 2010, 13, (8), 920-922.
31. Honey, G.D.; Suckling, J.; Zelaya, F.; Long, C.; Routledge, C.; Jackson, S.; Ng, V.; Fletcher, P.C.; Williams, S.C.; Brown, J.; Bullmore, E.T., Dopaminergic drug effects on physiological connectivity in a human corticostriato-thalamic system. Brain, 2003, 126, (Pt 8), 1767-1781. (Pubitemid 36917336)
32. Boyson, S.J.; McGonigle, P.; Luthin, G.R.; Wolfe, B.B.; Molinoff, P.B., Effects of chronic administration of neuroleptic and anticholinergic agents on densities of D2 dopamine and muscarinic cholinergic receptors in rat striatum. J Pharmacol Exp Ther, 1988, 244, (3), 987-993. (Pubitemid 18090117)
33. Wolffgramm, J.; Rommelspacher, H.; Buck, E., Ethanol reduces tolerance, sensitization, and up-regulation of D2-receptors after subchronic haloperidol. Pharmacol Biochem Behav, 1990, 36, (4), 907-914. (Pubitemid 20272315)
34. Samaha, A.N.; Seeman, P.; Stewart, J.; Rajabi, H.; Kapur, S., "Breakthrough" dopamine supersensitivity during ongoing antipsychotic treatment leads to treatment failure over time. J Neurosci, 2007, 27, (11), 2979-2986. (Pubitemid 46438984)
35. Chiodo, L.A.; Bunney, B.S., Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci, 1983, 3, (8), 1607-1619. (Pubitemid 13045297)
36. Valenti, O.; Cifelli, P.; Gill, K.M.; Grace, A.A., Antipsychotic drugs rapidly induce dopamine neuron depolarization block in a developmental rat model of schizophrenia. J Neurosci, 2011, 31, (34), 12330-12338.
37. Farber, N.B.; Nemmers, B.; Noguchi, K.K., Acute D2/D3 dopaminergic agonism but chronic D2/D3 antagonism prevents NMDA antagonist neurotoxicity. Biological psychiatry, 2006, 60, (6), 630-638. (Pubitemid 44402368)
38. Tandon, R., Antipsychotics in the treatment of schizophrenia: an overview. The Journal of clinical psychiatry, 2011, 72 Suppl 1, 4-8.
39. Leucht, S.; Tardy, M.; Komossa, K.; Heres, S.; Kissling, W.; Davis, J.M., Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane database of systematic reviews (Online), 2012, 5, CD008016.
40. Stephan, K.E.; Magnotta, V.A.; White, T.; Arndt, S.; Flaum, M.; O'Leary, D.S.; Andreasen, N.C., Effects of olanzapine on cerebellar functional connectivity in schizophrenia measured by fMRI during a simple motor task. Psychological medicine, 2001, 31, (6), 1065-1078. (Pubitemid 32725351)
41. Bertolino, A.; Blasi, G.; Caforio, G.; Latorre, V.; De Candia, M.; Rubino, V.; Callicott, J.H.; Mattay, V.S.; Bellomo, A.; Scarabino, T.; Weinberger, D.R.; Nardini, M., Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biological psychiatry, 2004, 56, (3), 190-197. (Pubitemid 38969152)
42. Snitz, B.E.; MacDonald, A., 3rd; Cohen, J.D.; Cho, R.Y.; Becker, T.; Carter, C.S., Lateral and medial hypofrontality in first-episode schizophrenia: functional activity in a medication-naive state and effects of short-term atypical antipsychotic treatment. The American journal of psychiatry, 2005, 162, (12), 2322-2329. (Pubitemid 41740211)
43. Keedy, S.K.; Rosen, C.; Khine, T.; Rajarethinam, R.; Janicak, P.G.; Sweeney, J.A., An fMRI study of visual attention and sensorimotor function before and after antipsychotic treatment in first-episode schizophrenia. Psychiatry research, 2009, 172, (1), 16-23.
44. Blasi, G.; Popolizio, T.; Taurisano, P.; Caforio, G.; Romano, R.; Di Giorgio, A.; Sambataro, F.; Rubino, V.; Latorre, V.; Lo Bianco, L.; Fazio, L.; Nardini, M.; Weinberger, D.R.; Bertolino, A., Changes in prefrontal and amygdala activity during olanzapine treatment in schizophrenia. Psychiatry research, 2009, 173, (1), 31-38.
45. Sambataro, F.; Blasi, G.; Fazio, L.; Caforio, G.; Taurisano, P.; Romano, R.; Di Giorgio, A.; Gelao, B.; Lo Bianco, L.; Papazacharias, A.; Popolizio, T.; Nardini, M.; Bertolino, A., Treatment with olanzapine is associated with modulation of the default mode network in patients with Schizophrenia. Neuropsychopharmacology, 2010, 35, (4), 904-912.
46. Lui, S.; Li, T.; Deng, W.; Jiang, L.; Wu, Q.; Tang, H.; Yue, Q.; Huang, X.; Chan, R.C.; Collier, D.A.; Meda, S.A.; Pearlson, G.; Mechelli, A.; Sweeney, J.A.; Gong, Q., Short-term effects of antipsychotic treatment on cerebral function in drug-naive first-episode schizophrenia revealed by "resting state" functional magnetic resonance imaging. Archives of general psychiatry, 2010, 67, (8), 783-792.
47. van Veelen, N.M.; Vink, M.; Ramsey, N.F.; van Buuren, M.; Hoogendam, J.M.; Kahn, R.S., Prefrontal lobe dysfunction predicts treatment response in medication-naive first-episode schizophrenia. Schizophrenia research, 2011, 129, (2-3), 156-162.
48. Agid, O.; Kapur, S.; Arenovich, T.; Zipursky, R.B., Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Archives of general psychiatry, 2003, 60, (12), 1228-1235. (Pubitemid 37494076)
49. Leucht, S.; Busch, R.; Hamann, J.; Kissling, W.; Kane, J.M., Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biological psychiatry, 2005, 57, (12), 1543-1549. (Pubitemid 40805384)
50. Greicius, M., Resting-state functional connectivity in neuropsychiatric disorders. Current opinion in neurology, 2008, 21, (4), 424-430.
51. Iannetti, G.D.; Wise, R.G., BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn Reson Imaging, 2007, 25, (6), 978-988. (Pubitemid 47081371)
52. Schlagenhauf, F.; Wustenberg, T.; Schmack, K.; Dinges, M.; Wrase, J.; Koslowski, M.; Kienast, T.; Bauer, M.; Gallinat, J.; Juckel, G.; Heinz, A., Switching schizophrenia patients from typical neuroleptics to olanzapine: effects on BOLD response during attention and working memory. Eur Neuropsychopharmacol, 2008, 18, (8), 589-599.
53. Fernandez-Seara, M.A.; Aznarez-Sanado, M.; Mengual, E.; Irigoyen, J.; Heukamp, F.; Pastor, M.A., Effects on resting cerebral blood flow and functional connectivity induced by metoclopramide: a perfusion MRI study in healthy volunteers. British journal of pharmacology, 2011, 163, (8), 1639-1652.
54. Stockton, M.E.; Rasmussen, K., Olanzapine, a novel atypical antipsychotic, reverses d-Amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology, 1996, 124, (1-2), 50-56. (Pubitemid 26112774)
55. Todorova, A.; Dimpfel, W., Multiunit Activity From The A9 And A10 Areas In Rats Following Chronic Treatment With Different Neuroleptic Drugs. European Neuropsychopharmacology, 1994, 4, (4), 491-501.
56. Zhang, J.; Wang, L.P.; Pitts, D.K., Prenatal haloperidol reduces the number of active midbrain dopamine neurons in rat offspring. Neurotoxicology and Teratology, 1996, 18, (1), 49-57. (Pubitemid 26075806)
57. Skarsfeldt, T., Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats -Acute and repeated treatment. Synapse, 1992, 10, (1), 25-33.
58. Stockton, M.E.; Rasmussen, K., Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology, 1996, 14, (2), 97-104. (Pubitemid 26050498)
59. Minabe, Y.; Hashimoto, K.; Shirayama, Y.; Ashby, C.R., Effect of the acute and chronic administration of the putative atypical antipsychotic drug Y-931 (8-fluoro-12(4-methylpiperazin-1-yl)-6H-l benzothieno 2,3b 1,5 benzodiazepine maleate) on spontaneously active rat midbrain dopamine neurons: An in vivo electrophysiological study. Synapse, 2004, 51, (1), 19-26. (Pubitemid 37421136)
60. Pietraszek, M.; Golembiowska, K.; Bijak, M.; Ossowska, K.; Wolfarth, S., Differential effects of chronic haloperidol and clozapine administration on glutamatergic transmission in the fronto-parietal cortex in rats: microdialysis and electrophysiological studies. Naunyn-Schmiedebergs Archives of Pharmacology, 2002, 366, (5), 417-424. (Pubitemid 35244904)
61. Gronier, B.S.; Rasmussen, K., Electrophysiological effects of acute and chronic olanzapine and fluoxetine in the rat prefrontal cortex. Neurosci. Lett., 2003, 349, (3), 196-200. (Pubitemid 37297811)
62. Homayoun, H.; Moghaddam, B., Fine-tuning of awake prefrontal cortex neurons by clozapine: Comparison with haloperidol and Ndesmethylclozapine. Biological psychiatry, 2007, 61, (5), 679-687. (Pubitemid 46328858)
63. Guzowski, J.F.; McNaughton, B.L.; Barnes, C.A.; Worley, P.F., Environment-specific expression of the immediate-early gene Arc in hippocampal neuronal ensembles. Nature neuroscience, 1999, 2, (12), 1120-1124. (Pubitemid 30126371)
64. Guzowski, J.F.; Setlow, B.; Wagner, E.K.; McGaugh, J.L., Experience dependent gene expression in the rat hippocampus after spatial learning: A comparison of the immediate-early genes Arc, c-fos, and zif268. Journal of Neuroscience, 2001, 21, (14), 5089-5098. (Pubitemid 32622934)
65. Hamilton, D.A.; Candelaria-Cook, F.T.; Akers, K.G.; Rice, J.P.; Maes, L.I.; Rosenberg, M.; Valenzuela, C.F.; Savage, D.D., Patterns of socialexperience-related c-fos and Arc expression in the frontal cortices of rats exposed to saccharin or moderate levels of ethanol during prenatal brain development. Behavioural brain research, 2010, 214, (1), 66-74.
66. Carrey, N.; Wilkinson, M., A review of psychostimulant-induced neuroadaptation in developing animals. Neurosci. Bull., 2011, 27, (3), 197-214.
67. Cochran, S.M.; McKerchar, C.E.; Morris, B.J.; Pratt, J.A., Induction of differential patterns of local cerebral glucose metabolism and immediateearly genes by acute clozapine and haloperidol. Neuropharmacology, 2002, 43, (3), 394-407. (Pubitemid 35257931)
68. Dawe, G.S.; Huff, K.D.; Vandergriff, J.L.; Sharp, T.; O'Neill, M.J.; Rasmussen, K., Olanzapine activates the rat locus coeruleus: In vivo electrophysiology and c-fos immunoreactivity. Biological psychiatry, 2001, 50, (7), 510-520. (Pubitemid 32971882)
69. Ohashi, K.; Hamamura, T.; Lee, Y.; Fujiwara, Y.; Suzuki, H.; Kuroda, S., Clozapine-And olanzapine-induced Fos expression in the rat medial prefrontal cortex is mediated by beta-Adrenoceptors. Neuropsychopharmacology, 2000, 23, (2), 162-169. (Pubitemid 30406900)
70. Deutch, A.Y.; Duman, R.S., The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization. Neuroscience, 1996, 70, (2), 377-389. (Pubitemid 126755251)
71. Deutch, A.Y.; Lewis, D.A.; Whitehead, R.E.; Elsworth, J.D.; Iadarola, M.J.; Redmond, D.E.; Roth, R.H., Effects of D-2 dopamine receptor antagonists on fos protein expression in the striatal complex and entorhinal cortex of the nonhuman primate. Synapse, 1996, 23, (3), 182-191. (Pubitemid 26230565)
72. Murphy, C.A.; Feldon, J., Interactions between environmental stimulation and antipsychotic drug effects on forebrain C-FOS activation. Neuroscience, 2001, 104, (3), 717-730. (Pubitemid 32607424)
73. Robertson, G.S.; Fibiger, H.C., Effects of olanzapine on regional c-Fos expression in rat forebrain. Neuropsychopharmacology, 1996, 14, (2), 105-110. (Pubitemid 26050499)
74. Macgibbon, G.A.; Lawlor, P.A.; Bravo, R.; Dragunow, M., Clozapine and haloperidol produce a differential pattern of immediate-early geneexpression in rat caudate-putamen, nucleus-Accumbens, lateral septum and islands-of-Calleja. Molecular Brain Research, 1994, 23, (1-2), 21-32. (Pubitemid 24090978)
75. Fujimura, M.; Hashimoto, K.; Yamagami, K., The effect of the antipsychotic drug mosapramine on the expression of Fos protein in the rat brain -Comparison with haloperidol, clozapine and risperidone. Life Sciences, 2000, 67, (23), 2865-2872.
76. Nguyen, T.V.; Kosofsky, B.E.; Birnbaum, R.; Cohen, B.M.; Hyman, S.E., Differential expression of c-fos and zif268 in rat striatum after haloperidol, clozapine, and amphetamine. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, (10), 4270-4274.
77. Fumagalli, F.; Frasca, A.; Racagni, G.; Riva, M.A., Antipsychotic drugs modulate Arc expression in the rat brain. European Neuropsychopharmacology, 2009, 19, (2), 109-115.
78. Nakahara, T.; Kuroki, T.; Hashimoto, K.; Hondo, H.; Tsutsumi, T.; Motomura, K.; Ueki, H.; Hirano, M.; Uchimura, H., Effect of atypical antipsychotics on phencyclidine-induced expression of arc in rat brain. Neuroreport, 2000, 11, (3), 551-555. (Pubitemid 30120475)
79. Iasevoli, F.; Fiore, G.; Cicale, M.; Muscettola, G.; de Bartolomeis, A., Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions. Psychiatry research, 2010, 177, (1-2), 255-260.
80. Guzowski, J.F.; Lyford, G.L.; Stevenson, G.D.; Houston, F.P.; McGaugh, J.L.; Worley, P.F.; Barnes, C.A., Inhibition of activity-dependent arc protein expression in the rat hippocampus impairs the maintenance of long-term potentiation and the consolidation of long-term memory. Journal of Neuroscience, 2000, 20, (11), 3993-4001. (Pubitemid 30365669)
81. Rodriguez, J.J.; Garcia, D.R.; Nakabeppu, Y.; Pickel, V.M., FosB in rat striatum: Normal regional distribution and enhanced expression after 6-month haloperidol administration. Synapse, 2001, 39, (2), 122-132. (Pubitemid 32104017)
82. Verma, V.; Lim, E.P.; Han, S.P.; Nagarajah, R.; Dawe, G.S., Chronic highdose haloperidol has qualitatively similar effects to risperidone and clozapine on immediate-early gene and tyrosine hydroxylase expression in the rat locus coeruleus but not medial prefrontal cortex. Neuroscience Research, 2007, 57, (1), 17-28. (Pubitemid 46073244)
83. VahidAnsari, F.; Nakabeppu, Y.; Robertson, G.S., Contrasting effects of chronic clozapine, Seroquel(TM) (ICI 204,636) and haloperidol administration on Delta FosB-like immunoreactivity in the rodent forebrain. European Journal of Neuroscience, 1996, 8, (5), 927-936. (Pubitemid 26148354)
84. Leuner, B.; Falduto, J.; Shors, T.J., Associative memory formation increases the observation of dendritic spines in the hippocampus. Journal of Neuroscience, 2003, 23, (2), 659-665. (Pubitemid 36139564)
85. Moser, M.B.; Trommald, M.; Andersen, P., An Increase In Dendritic Spine Density On Hippocampal CA1 Pyramidal Cells Following Spatial-Learning In Adult-Rats Suggests The Formation Of New Synapses. Proceedings of the National Academy of Sciences of the United States of America, 1994, 91, (26), 12673-12675.
86. Kolb, B.; Whishaw, I.Q., Brain plasticity and behavior. Annual Review of Psychology, 1998, 49, 43-64. (Pubitemid 128491767)
87. Harris, K.M.; Kater, S.B., Dendritic Spines -Cellular Specializations Imparting Both Stability And Flexibility To Synaptic Function. Annual Review of Neuroscience, 1994, 17, 341-371. (Pubitemid 24117034)
88. Hamilton, D.A.; Akers, K.G.; Rice, J.P.; Johnson, T.E.; Candelaria-Cook, F.T.; Maes, L.I.; Rosenberg, M.; Valenzuela, C.F.; Savage, D.D., Prenatal exposure to moderate levels of ethanol alters social behavior in adult rats: Relationship to structural plasticity and immediate early gene expression in frontal cortex. Behavioural brain research, 2010, 207, (2), 290-304.
89. van Praag, H.; Kempermann, G.; Gage, F.H., Neural consequences of environmental enrichment. Nature Reviews Neuroscience, 2000, 1, (3), 191-198.
90. Kolb, B.; Gibb, R.; Gorny, G., Experience-dependent changes in dendritic arbor and spine density in neocortex vary qualitatively with age and sex. Neurobiology of Learning and Memory, 2003, 79, (1), 1-10. (Pubitemid 36071184)
91. Hamilton, D.A.; Kolb, B., Differential effects of nicotine and complex housing on subsequent experience-dependent structural plasticity in the nucleus accumbens. Behavioral Neuroscience, 2005, 119, (2), 355-365. (Pubitemid 40547942)
92. Wosiski-Kuhn, M.; Stranahan, A.M., Transient increases in dendritic spine density contribute to dentate gyrus long-term potentiation. Synapse, 2012, 66, (7), 661-664.
93. Purpura, D.P., Dendritic Spine Dysgenesis And Mental-Retardation. Science (New York, N.Y, 1974, 186, (4169), 1126-1128.
94. Glantz, L.A.; Lewis, D.A., Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Archives of general psychiatry, 2000, 57, (1), 65-73. (Pubitemid 30035660)
95. Ide, M.; Lewis, D.A., Altered Cortical CDC42 Signaling Pathways in Schizophrenia: Implications for Dendritic Spine Deficits. Biological psychiatry, 2010, 68, (1), 25-32.
96. Pierri, J.N.; Volk, C.L.E.; Auh, S.; Sampson, A.; Lewis, D.A., Decreased somal size of deep layer 3 pyramidal neurons in the prefrontal cortex of subjects with schizophrenia. Archives of general psychiatry, 2001, 58, (5), 466-473. (Pubitemid 32411327)
97. Kelley, J.J.; Gao, X.M.; Tamminga, C.A.; Roberts, R.C., The effect of chronic haloperidol treatment on dendritic spines in the rat striatum. Experimental neurology, 1997, 146, (2), 471-478. (Pubitemid 27381854)
98. Roberts, R.C., Effect of chronic olanzapine treatment on striatal synaptic organization. Synapse, 2001, 39, (1), 8-15.
99. Roberts, R.C.; Gaither, L.A.; Gao, X.M.; Kashyap, S.M.; Tamminga, C.A., Ultrastructural Correlates Of Haloperidol-Induced Oral Dyskinesias In Rat Striatum. Synapse, 1995, 20, (3), 234-243.
100. Benes, F.M.; Paskevich, P.A.; Davidson, J.; Domesick, V.B., The Effects Of Haloperidol On Synaptic Patterns In The Rat Striatum. Brain Research, 1985, 329, (1-2), 265-273.
101. Frost, D.O.; Page, S.C.; Carroll, C.; Kolb, B., Early Exposure to Haloperidol or Olanzapine Induces Long-Term Alterations of Dendritic Form. Synapse, 2010, 64, (3), 191-199.
102. Wang, H.D.; Deutch, A.Y., Dopamine depletion of the prefrontal cortex induces dendritic spine loss: Reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology, 2008, 33, (6), 1276-1286. (Pubitemid 351521724)
103. Kolb, B.; Gorny, G.; Li, Y.L.; Samaha, A.N.; Robinson, T.E., Amphetamine or cocaine limits the ability of later experience to promote structural plasticity in the neocortex and nucleus accumbens. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, (18), 10523-10528. (Pubitemid 37071911)
104. Robinson, T.E.; Kolb, B., Structural plasticity associated with exposure to drugs of abuse. Neuropharmacology, 2004, 47, 33-46. (Pubitemid 39298251)
105. Flores, C.; Wen, X.L.; Labelle-Dumais, C.; Kolb, B., Chronic phencyclidine treatment increases dendritic spine density in prefrontal cortex and nucleus accumbens neurons. Synapse, 2007, 61, (12), 978-984. (Pubitemid 350271777)
106. Vincent, S.L.; McSparren, J.; Wang, R.Y.; Benes, F.M., Edicience for ultrastructural-changes in cortical axodendritic synapses follwing long-term treatment with haloperidol or clozapine. Neuropsychopharmacology, 1991, 5, (3), 147-155.
107. Elsworth, J.D.; Hajszan, T.; Leranth, C.; Roth, R.H., Loss of asymmetric spine synapses in dorsolateral prefrontal cortex of cognitively impaired phencyclidine-treated monkeys. International Journal of Neuropsychopharmacology, 2011, 14, (10), 1411-1415.
108. Elsworth, J.D.; Morrow, B.A.; Hajszan, T.; Leranth, C.; Roth, R.H., Phencyclidine-induced Loss of Asymmetric Spine Synapses in Rodent Prefrontal Cortex is Reversed by Acute and Chronic Treatment with Olanzapine. Neuropsychopharmacology, 2011, 36, (10), 2054-2061.
109. Pillai, A.; Mahadik, S.P., Differential effects of haloperidol and olanzapine on levels of vascular endothelial growth factor and angiogenesis in rat hippocampus. Schizophrenia research, 2006, 87, (1-3), 48-59. (Pubitemid 44428128)